Exact Sciences Corporation

NasdaqCM:EXAS 株式レポート

時価総額：US$20.0b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Exact Sciences 過去の業績

過去 基準チェック /06

Exact Sciencesは4.7%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで30.9%毎年増加している。売上は成長しており、年平均14.5%の割合である。

主要情報

4.70%

収益成長率

8.95%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率14.50%
株主資本利益率-8.66%
ネット・マージン-6.40%
前回の決算情報31 Dec 2025

最近の業績更新

Recent updates

ナラティブの更新 • Mar 16

EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward

The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.
ナラティブの更新 • Mar 02

EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery

Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.
ナラティブの更新 • Feb 16

EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward

Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.
ナラティブの更新 • Feb 02

EXAS: Takeout Premium And Downgrades Will Frame Upcoming Deal Closure Risk

Analysts made a modest upward adjustment to their fair value estimate for Exact Sciences to $105.81, describing it as largely in line with the $105 per share Abbott takeout price and supported by updated assumptions around discount rate, profit margin, and future P/E in recent research following the wave of rating downgrades tied to the announced acquisition. Analyst Commentary Street research around Exact Sciences has shifted quickly toward treating the shares as a deal proxy after the announced US$105 per share cash offer from Abbott.
ナラティブの更新 • Jan 19

EXAS: Abbott Takeover Agreement Will Anchor Upside To Deal Completion

Analysts have lifted their fair value estimate for Exact Sciences from $77.68 to $116.46. This reflects updated assumptions around slightly higher revenue growth, a revised profit margin outlook, a modestly higher discount rate, and a higher future P/E multiple in light of the agreed Abbott takeout price of $105 per share and the cluster of Street targets around that level.
ナラティブの更新 • Jan 04

EXAS: Abbott Deal At $105 Will Define Shares With Balanced Prospects

Analysts have raised their price target on Exact Sciences to approximately $93 from about $48, citing the $105 per share Abbott takeout as validation of higher long term profitability and valuation multiples, despite slightly tempered standalone growth expectations. Analyst Commentary Bearish analysts largely framed the Abbott transaction as crystallizing value and limiting further upside, prompting a wave of rating downgrades to Hold, Neutral, Equal Weight, and Market Perform.
ナラティブの更新 • Dec 15

EXAS: Takeout Premium Will Shift Focus To Deal Completion Risk Balancing Upside

Analysts have raised their price targets on Exact Sciences toward the agreed Abbott takeout price of $105 per share. This reflects improved growth and margin expectations alongside the belief that the acquisition premium fairly captures the company’s long term value.
ナラティブの更新 • Dec 01

EXAS: Acquisition By Abbott Will Shift Focus Toward Deal Closure And Approval

The analyst price target for Exact Sciences has increased from $82.10 to $103.67 following the announcement of its acquisition by Abbott for $105 per share. Analysts cite the takeover premium and strong strategic rationale as key drivers behind the upward revision.
Seeking Alpha • Nov 20

Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know

Summary Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue growth, record Q3 results, and promising new products like CancerGuard but remains unprofitable with fierce competition in cancer screening. Abbott Laboratories seeks to revitalize growth and expand its diagnostics portfolio, betting on Exact Sciences' MCED technology and established products like Cologuard despite high acquisition costs. Maintain Hold ratings on both Exact Sciences and Abbott Laboratories; Exact shareholders benefit from the deal, while Abbott's upside depends on successful integration and MCED market adoption. Read the full article on Seeking Alpha
分析記事 • Nov 20

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too

Despite an already strong run, Exact Sciences Corporation ( NASDAQ:EXAS ) shares have been powering on, with a gain of...
ナラティブの更新 • Nov 17

EXAS: Revenue Momentum And Expanded Guidance Will Drive Shares Higher

Analysts have raised their price target for Exact Sciences from approximately $70 to $82, citing stronger-than-expected revenue growth, margin expansion, and several upward revisions in expectations following earnings. Analyst Commentary Recent analyst updates reflect growing optimism about Exact Sciences' prospects, particularly in light of strong revenue growth, expanded guidance, and successful execution across its core business lines.
ナラティブの更新 • Nov 01

EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data

Analysts have raised their price target for Exact Sciences to $70 from $60, citing continued strength in its core Cologuard franchise as well as expanding opportunities in cancer screening and detection. Analyst Commentary Recent analyst activity for Exact Sciences reflects a dynamic mix of optimism and caution, as the company continues to execute on its core strengths while navigating evolving market expectations.
ナラティブの更新 • Oct 18

Humana, Centene And Medicare Coverage Will Increase Screening Access

Analysts have raised their price target for Exact Sciences to approximately $70 from $65, citing strong momentum from new revenue opportunities and increased confidence in long-term growth drivers. Analyst Commentary Recent analyst actions on Exact Sciences reflect notable shifts in sentiment, both positive and cautious, following the company’s latest performance and strategic moves.
ナラティブの更新 • Oct 03

Humana, Centene And Medicare Coverage Will Increase Screening Access

Analysts have modestly raised their price target for Exact Sciences, increasing it from $64.01 to $65.38. They cite incremental near-term revenue growth drivers, ongoing margin expansion, and improved cash flow prospects as key reasons for the upward adjustment.
ナラティブの更新 • Sep 12

Humana, Centene And Medicare Coverage Will Increase Screening Access

Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.
分析記事 • Sep 08

Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders are no doubt pleased to see that the share price has bounced...
ナラティブの更新 • Aug 08

Humana, Centene And Medicare Coverage Will Increase Screening Access

Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).
User avatar
新しいナラティブ • Apr 27

Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes

Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.
Seeking Alpha • Aug 18

Exact Sciences: Cost Optimization And Product Strength

Summary Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability. It is likely to suffer from volatility risks as it continues to strike a balance between growth and profitability. The stock is a buy with a potential 27% upside also given the way it is improving its competitive position and leveraging AI for accelerating data analysis. Read the full article on Seeking Alpha
Seeking Alpha • Jun 11

Exact Sciences: Still No Reason To Own

Summary We are revisiting oncology testing company Exact Sciences Corporation today for the first time in nearly a year and a half. The shares have been cut by more than half since last summer, despite revenue growth in the low teens and strong support from the analyst firm community. Is it time to buy the dip?  An updated analysis around Exact Sciences follows in the paragraphs below. Read the full article on Seeking Alpha

収支内訳

Exact Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:EXAS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Dec 253,247-2081,891522
30 Sep 253,082-9871,821429
30 Jun 252,940-1,0051,773413
31 Mar 252,828-1,0201,724426
31 Dec 242,759-1,0291,679431
30 Sep 242,692-2141,666449
30 Jun 242,612-1751,657459
31 Mar 242,535-2401,665442
31 Dec 232,500-2041,646427
30 Sep 232,406-2821,625405
30 Jun 232,301-4321,612385
31 Mar 232,200-5171,624387
31 Dec 222,084-6241,650394
30 Sep 222,005-7161,695388
30 Jun 221,938-7351,682372
31 Mar 221,852-7451,609372
31 Dec 211,767-5961,538386
30 Sep 211,760-7931,370744
30 Jun 211,712-8291,249700
31 Mar 211,546-7201,126626
31 Dec 201,491-8241,071554
30 Sep 201,321-327961151
30 Jun 201,131-165875154
31 Mar 201,062-136802151
31 Dec 19876-213738140
30 Sep 19724-216606116
30 Jun 19623-22155199
31 Mar 19526-21949384
31 Dec 18454-17542767
30 Sep 18399-14336960
30 Jun 18353-12432654
31 Mar 18308-11929349
31 Dec 17266-11426342
30 Sep 17214-13024137
30 Jun 17169-14121932
31 Mar 17133-15520531
31 Dec 1699-16719033
30 Sep 1679-17017636
30 Jun 1663-17516738
31 Mar 1650-16915437
31 Dec 1539-15814034
30 Sep 1527-15012830
30 Jun 1514-13911228
31 Mar 156-1209027

質の高い収益: EXASは現在利益が出ていません。

利益率の向上: EXASは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: EXASは利益を出していないが、過去 5 年間で年間4.7%の割合で損失を削減してきた。

成長の加速: EXASの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: EXASは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。

株主資本利益率

高いROE: EXASは現在利益が出ていないため、自己資本利益率 ( -8.66% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/03/24 02:29
終値2026/03/20 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Exact Sciences Corporation 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27

アナリスト機関
Catherine Ramsey SchulteBaird
Bruce JacksonBenchmark Company
Raymond MyersBenchmark Company